**Table 4:** Frequencies of clinical-pathological characteristics according to immunohistochemical αβ-crystallin and laminin-332 positivity or basal/penta negative subtypes.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **All patients** **n = 69** | **αβ-Crystallin negative****n = 18** | **αβ-Crystallin positive****n = 48** | **Laminin-332****negative****n = 25** | **Laminin-332 positive****n = 44** | **Basal (CK5/6 and/or EGFR positive)****n = 57** | **Penta negative (CK5/6 and EGFR negative)****n = 12** |
| **Age** |  |  |  |  |  |  |  |
| < 40 years  | 5 (9%) | 2 (13%) | 3 (8%) | 0 | 5 (15%) | 5 (10%) | 0 |
|  ≥ 40 years | 52 (91%) | 13 (87%) | 36 (92%) | 23 (100%) | 29 (85%) | 43 (90%) | 9 (100%) |
| Total | 57 | 15 | 39 | 23 | 31 | 48 | 9 |
| **Tumor grade**  |  |  |  |  |  |  |  |
|  Grade 1 | 3 (5%) | 1 (8%) | 1 (3%) | 2 (10%) | 1 (3%) | 3 (6%) | 0 |
|  Grade 2 | 15 (27%) | 5 (38%) | 9 (23%) | 9 (43%) | 6 (17%) | 11 (23%) | 4 (44%) |
|  Grade 3 | 38 (68%) | 7 (54%) | 30 (75%) | 10 (48%) | 28 (80%) | 33 (70%) | 5 (56%) |
| Total | 56 | 13 | 40 | 21 | 35 | 47 | 9 |
| **LN involvement**  |  |  |  |  |  |  |  |
|  Positive |  |  |  |  |  |  |  |
|  1 to 3 + nodes | 15 (26%) | 7 (44%) | 8 (21%) | 8 (40%) | 7 (19%) | 11 (23%) | 4 (44%) |
|  ≥ 4 + nodes | 16 (28%) | 3 (19%) | 11 (29%) | 7 (35%) | 9 (24%) | 15 (31%) | 1 (11%) |
|  Negative | 26 (46%) | 6 (38%) | 19 (50%) | 5 (25%) | 21 (57%) | 22 (46%) | 4 (44%) |
| Total | 57 | 16 | 38 | 20 | 37 | 48 | 9 |
| **Histological subtypes**  |  |  |  |  |  |  |  |
|  Invasive ductal carcinoma NOS | 59 (95%) | 15 (88%) | 41 (98%) | 21 (91%) | 38 (97%) | 51 (96%) | 8 (89%) |
|  Mixed ductal and lobular carcinoma | 1 (2%) | 1 (6%) | 0 | 1 (4%) | 0 | 0 | 1 (11%) |
|  Metaplastic carcinoma | 1 (2%) | 0 | 1 (2%) | 1 (4%) | 0 | 1 (2%) | 0 |
|  Medullary-like carcinoma | 1 (2%) | 1 (6%) | 0 | 0 | 1 (3%) | 1 (2%) | 0 |
| Total | 62 | 17 | 42 | 23 | 39 | 53 | 9 |
| **Lymphovascular invasion** |  |  |  |  |  |  |  |
|  Yes | 17 (45%) | 6 (67%) | 11 (41%) | 9 (75%) | 8 (31%) | 13 (41%) | 4 (67%) |
|  No | 21 (55%) | 3 (33%) | 16 (59%) | 3 (25%) | 18 (69%) | 19 (59%) | 2 (33%) |
| Total | 38 | 9 | 27 | 12 | 26 | 32 | 6 |
|  |  |  |  |  |  |  |  |
| **Tumor size**  |  |  |  |  |  |  |  |
| < 2 cm  | 15 (26%) | 6 (38%) | 8 (21%) | 0 | 15 (40%) | 14 (29%) | 1 (11%) |
|  2 to 4.9 cm | 32 (56%) | 7 (44%) | 24 (63%) | 16 (84%) | 16 (42%) | 25 (52%) | 7 (78%) |
|  ≥ 5.0 cm | 10 (18%) | 3 (19%) | 6 (16%) | 3 (16%) | 7 (18%) | 9 (19%) | 1 (11%) |
| Total | 57 | 16 | 38 | 19 | 38 | 48 | 9 |
| **Cumulative survival probability\***  |  |  |  |  |  |  |  |
| 60 months  | 0.64 | 0.67 | 0.55 | 0.42 | 0.75 | 0.67 | 0.37 |
| Number of patients followed | 55 | 15 | 37 | 23 | 32 | 46 | 9 |
| Log-rank P-value |  | 0.129 |  | 0.054 |  |  | 0.360 |

\*No failure (death) occurred at age 60 months. Cumulative survival probability reported at the table; that for 76 or 78 mo.\*All sample*: cumulative survival probability at 59 mo = 0.67; at 76 mo = 0.64;

*αβ-Crystallin negative*: cumulative survival probability at 59 mo = 0.77; at 76 mo = 0.67;
*αβ-Crystallin positive*: cumulative survival probability at 54 mo = 0.59; at 78 mo = 0.55;
*Laminin-5 negative*: cumulative survival probability at 59 mo = 0.50; at 76 mo = 0.42;

*Laminin-5 positive:* cumulative survival probability at 33 mo = 0.79; at 78 mo = 0.75;

*Basal:* cumulative survival probability at 54 mo = 0.70; at 78 mo = 0.67;
*Pentanegative:* cumulative survival probability at 59 mo = 0.56; at 76 mo = 0.37.